Key result
Intramuscular immunization with the recombinant adenovirus rAdv-P12A3CG38SF48S-GD protected 100% of guinea pigs against challenge with type A foot-and-mouth disease virus.
Why the study?
Type A Foot-and-mouth disease virus has been detected on China's pig farms since 2015, and new approaches were needed to overcome the shortcomings of inactive FMDV vaccines.
Absolute Event Rate: 100% vs 0%
A recombinant adenovirus expressing mutated FMDV capsid proteins protected 100% of guinea pigs against challenge, demonstrating potential as a novel vaccine.
Supports further preclinical development of Ad5-vectored FMDV vaccines; leaves open translation to commercial swine use.
Type A Foot-and-mouth disease virus (FMDV) has been detected on China’s pig farms since 2015, and all suspected samples have been strain A/GDMM/CHA/2013. To overcome the shortcomings of inactive FMDV vaccines, we expressed the capsid protein precursor P1-2A and mutated viral 3C protease of FMDV strain A/GDMM/CHA/2013 in a replication-deficient human adenovirus type 5 vector in this study. A significant humoral immune response, T-cell-mediated antiviral response, and mucosa-mediated antiviral response were induced by the adenovirus-vectored FMDV vaccines in BALB/c mice. Immunization of guinea pigs with the adenovirus-vectored FMD vaccines induced significant neutralizing antibodies and anti-FMDV IgA antibodies. The recombinant adenovirus rAdv-P12A3CG38S F48S-GD protected 100% of guinea pigs against challenge when administered intramuscularly. Our study demonstrated the potential utility of rAdv-P12A3CG38S F48S-GD as a vaccine against type A FMDV.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2020) studied Foot-and-mouth disease virus (FMDV) infection (n=63). rAdv-P12A3CG38SF48S-GD vs. WtAdv (control adenovirus) was evaluated on Protection against FMDV challenge (no lesions on uninjected footpads). Intramuscular immunization with the recombinant adenovirus rAdv-P12A3CG38SF48S-GD protected 100% of guinea pigs against challenge with type A foot-and-mouth disease virus.